HUE037649T2 - (Tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-il vegyületek, mint duális aktivitású H1 inverz agonisták/5-HT2A antagonisták - Google Patents
(Tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-il vegyületek, mint duális aktivitású H1 inverz agonisták/5-HT2A antagonistákInfo
- Publication number
- HUE037649T2 HUE037649T2 HUE12735409A HUE12735409A HUE037649T2 HU E037649 T2 HUE037649 T2 HU E037649T2 HU E12735409 A HUE12735409 A HU E12735409A HU E12735409 A HUE12735409 A HU E12735409A HU E037649 T2 HUE037649 T2 HU E037649T2
- Authority
- HU
- Hungary
- Prior art keywords
- benzoxazepin
- thieno
- piperazin
- compounds
- inverse agonists
- Prior art date
Links
- -1 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS Chemical class 0.000 title 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 title 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505685P | 2011-07-08 | 2011-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE037649T2 true HUE037649T2 (hu) | 2018-09-28 |
Family
ID=46513872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12735409A HUE037649T2 (hu) | 2011-07-08 | 2012-07-02 | (Tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-il vegyületek, mint duális aktivitású H1 inverz agonisták/5-HT2A antagonisták |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9481688B2 (enExample) |
| EP (1) | EP2729474B1 (enExample) |
| JP (1) | JP6050813B2 (enExample) |
| KR (1) | KR101582429B1 (enExample) |
| CN (1) | CN103703008B (enExample) |
| AU (1) | AU2012283035B2 (enExample) |
| BR (1) | BR112014000379A2 (enExample) |
| CA (1) | CA2840217C (enExample) |
| DK (1) | DK2729474T3 (enExample) |
| EA (1) | EA023460B1 (enExample) |
| ES (1) | ES2665035T3 (enExample) |
| HR (1) | HRP20180475T1 (enExample) |
| HU (1) | HUE037649T2 (enExample) |
| IN (1) | IN2014MN00144A (enExample) |
| LT (1) | LT2729474T (enExample) |
| MX (1) | MX341132B (enExample) |
| NO (1) | NO2729474T3 (enExample) |
| PL (1) | PL2729474T3 (enExample) |
| PT (1) | PT2729474T (enExample) |
| RS (1) | RS57207B1 (enExample) |
| SI (1) | SI2729474T1 (enExample) |
| WO (1) | WO2013009517A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX365594B (es) | 2013-01-14 | 2019-06-07 | Lilly Co Eli | Compuestos de (tieno [2,3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo de actividad doble como agonista inversos de h1/antagonistas de 5-ht2a. |
| TW201625644A (zh) | 2014-04-29 | 2016-07-16 | 美國禮來大藥廠 | 作為選擇性５－ＨＴＡ反向促效劑之（噻吩并［２，３－ｂ］［１，５］苯并氧氮呯－４－基）哌嗪－１－基化合物 |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| CN108371660B (zh) * | 2017-12-14 | 2020-03-10 | 五邑大学 | 一种四氢环戊二烯并吡咯化合物及其衍生物的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| CA2386092A1 (en) * | 1999-09-29 | 2001-04-05 | Yao-Chang Xu | Piperidine derivatives |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| US7807828B2 (en) * | 2005-08-11 | 2010-10-05 | Hypnion, Inc. | Olanzapine analogs and methods of use thereof |
| DK2137180T3 (da) * | 2007-03-15 | 2012-07-02 | Andaman Therapeutics Inc | Dibenzo[B,F][1,4]oxazapinforbindelser |
| CN102105059B (zh) * | 2008-05-27 | 2015-09-30 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
| GB0910009D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxo Group Ltd | Novel compounds |
| AR084867A1 (es) * | 2011-02-07 | 2013-07-10 | Lilly Co Eli | Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual |
| KR101596607B1 (ko) * | 2011-08-30 | 2016-02-22 | 일라이 릴리 앤드 캄파니 | 이중 활성 H1 역 효능제/5-HT2A 길항제로서의 (티에노[2,3-b][1,5]벤족사제핀-4-일)피페라진-1-일 화합물 |
-
2012
- 2012-07-02 WO PCT/US2012/045254 patent/WO2013009517A1/en not_active Ceased
- 2012-07-02 CA CA2840217A patent/CA2840217C/en not_active Expired - Fee Related
- 2012-07-02 DK DK12735409.0T patent/DK2729474T3/en active
- 2012-07-02 US US14/125,320 patent/US9481688B2/en active Active
- 2012-07-02 PL PL12735409T patent/PL2729474T3/pl unknown
- 2012-07-02 CN CN201280031201.7A patent/CN103703008B/zh active Active
- 2012-07-02 HR HRP20180475TT patent/HRP20180475T1/hr unknown
- 2012-07-02 SI SI201231263T patent/SI2729474T1/en unknown
- 2012-07-02 PT PT127354090T patent/PT2729474T/pt unknown
- 2012-07-02 RS RS20180568A patent/RS57207B1/sr unknown
- 2012-07-02 LT LTEP12735409.0T patent/LT2729474T/lt unknown
- 2012-07-02 EA EA201391706A patent/EA023460B1/ru not_active IP Right Cessation
- 2012-07-02 NO NO12735409A patent/NO2729474T3/no unknown
- 2012-07-02 AU AU2012283035A patent/AU2012283035B2/en not_active Ceased
- 2012-07-02 ES ES12735409.0T patent/ES2665035T3/es active Active
- 2012-07-02 MX MX2014000337A patent/MX341132B/es active IP Right Grant
- 2012-07-02 JP JP2014519227A patent/JP6050813B2/ja active Active
- 2012-07-02 EP EP12735409.0A patent/EP2729474B1/en active Active
- 2012-07-02 KR KR1020147000119A patent/KR101582429B1/ko not_active Expired - Fee Related
- 2012-07-02 BR BR112014000379A patent/BR112014000379A2/pt not_active IP Right Cessation
- 2012-07-02 HU HUE12735409A patent/HUE037649T2/hu unknown
-
2014
- 2014-01-23 IN IN144MUN2014 patent/IN2014MN00144A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014000337A (es) | 2014-11-13 |
| KR101582429B1 (ko) | 2016-01-04 |
| IN2014MN00144A (enExample) | 2015-06-19 |
| CN103703008A (zh) | 2014-04-02 |
| NO2729474T3 (enExample) | 2018-08-11 |
| AU2012283035B2 (en) | 2015-07-30 |
| WO2013009517A1 (en) | 2013-01-17 |
| PT2729474T (pt) | 2018-06-05 |
| AU2012283035A1 (en) | 2014-01-16 |
| KR20140029512A (ko) | 2014-03-10 |
| EA201391706A1 (ru) | 2014-04-30 |
| CA2840217C (en) | 2016-03-22 |
| BR112014000379A2 (pt) | 2017-01-10 |
| SI2729474T1 (en) | 2018-04-30 |
| PL2729474T3 (pl) | 2018-08-31 |
| EP2729474A1 (en) | 2014-05-14 |
| CA2840217A1 (en) | 2013-01-17 |
| US9481688B2 (en) | 2016-11-01 |
| MX341132B (es) | 2016-08-09 |
| JP6050813B2 (ja) | 2016-12-21 |
| HRP20180475T1 (hr) | 2018-06-15 |
| US20140121199A1 (en) | 2014-05-01 |
| RS57207B1 (sr) | 2018-07-31 |
| DK2729474T3 (en) | 2018-05-22 |
| EP2729474B1 (en) | 2018-03-14 |
| CN103703008B (zh) | 2015-11-25 |
| EA023460B1 (ru) | 2016-06-30 |
| LT2729474T (lt) | 2018-05-10 |
| JP2014518280A (ja) | 2014-07-28 |
| ES2665035T3 (es) | 2018-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201400874B (en) | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | |
| IL266285A (en) | Methods for the production of tian compounds [d - 3,2] pyrimidine | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| LT2857404T (lt) | Imidazo[1,2-b]piridazino dariniai, kaip kinazės inhibitoriai | |
| IL227496B (en) | Pyrazolo[4,3–b]pyridines are converted as drugs | |
| SG11201402197UA (en) | [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 | |
| IL232304A (en) | [3,2,1] triazolo [5,4– d] pyrimidine derivatives as cannabinoid receptor type 2 agonists [3,2,1] triazolo [5,4– d] pyrimidine as cannabinoid receptor 2 agonists | |
| IL232717A0 (en) | 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives | |
| SG11201408816QA (en) | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | |
| PT2729474T (pt) | Compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ilo tendo actividade dual como agonistas inversos de h1/antagonistas de 5-ht2a | |
| SG11201500883YA (en) | 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | |
| SI2683719T1 (sl) | SUBSTITUIRANE SPOJINE ((5H-PIROLO(2,1-c) (1,4)BENZODIAZEPIN-11-IL)PIPERAZIN-1-IL)2,2-DIMETILPROPANOJSKE KISLINE KOT DVOJNO AKTIVNI H1 INVERZNI AGONISTI/5-HT2A ANTAGONISTI | |
| ZA201504041B (en) | (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity h1 inverse agonists/5-ht2a antagonists | |
| PL390846A1 (pl) | Pochodne 5,11-dimetylo-5H-indolo[2,3-b]chinoliny |